Purchase of an Operetta High Content Screening Reader

购买 Operetta 高内容放映阅读器

• 批准号: 8052285
• 负责人: PAUL M LIEBERMAN
• 金额: $ 40.69万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052285
• 关键词: Advisory Committees; Architecture; Atherosclerosis; Biological Assay; Cells; Chromatin; Communities; Data; Development; Diabetes Mellitus; Funding; Funding Applicant; Gene Expression; Herpesviridae; Image; Image Analysis; Inflammation; Lead; Maintenance; Malignant Neoplasms; MicroRNAs; Microscopy; Minor; Molecular; Neoplasm Metastasis; Pennsylvania; Reader; Research; Research Personnel; Resource Sharing; Screening procedure; Signal Transduction; Small Interfering RNA; Small Molecule Chemical Library; Support System; Surveys; System; Systems Biology; Technology; The Wistar Institute; United States National Institutes of Health; Universities; Virus Diseases; Wound Healing; base; cellular targeting; cofactor; epithelial to mesenchymal transition; high throughput screening; high throughput technology; human disease; instrument; medical schools; migration; miniaturize; nucleocytoplasmic transport; operation; research study; small hairpin RNA; tissue regeneration; tumor

DESCRIPTION (provided by applicant): Funds are requested to purchase a Perkin Elmer Operetta benchtop automated high-throughput, high- content imaging system. At present, no such instrument is available to the Wistar Institute or the neighboring research community at the University of Pennsylvania or Drexel University. The Wistar Institute has recently established a Molecular Screening Facility to support screening of shRNA, siRNA, miRNA, and small molecule chemical libraries in microtiter plates. The facility has made great progress in developing assays that utilize whole-well readouts. However neither the Molecular Screening nor Microscopy Facility at the Wistar Institute have the capability to support high-content screening. Furthermore, a survey of the neighboring University of Pennsylvania and Drexel School of Medicine indicate that access to this technology as a shared resource to support screening experiments is inadequate in our research community. Numerous investigators at Wistar have requested the facility expand its capabilities into high- content cell-based screening assays. The requested Operetta will be located in the Wistar Institute Molecular Screening Facility, which was established in 2008 and is dedicated to maintaining automated, high-throughput technologies required to support systems biology approaches to identify and validate cellular targets and/or lead molecules to treat human diseases, including cancer, diabetes, inflammation, and atherosclerosis. The unique features of the Operetta will greatly expand imaging capabilities at Wistar to include automated high-throughput acquisition and quantitative analysis of image data. Most importantly the Operetta will immediately impact the ability of 8 Major NIH-funded users and a group of Minor users to develop cell-based high-throughput screening assays that focus on the analysis of cells and their molecular components. An internal advisory committee comprised of users and senior staff from the Wistar Institute will oversee the operation, maintenance, and equitable access to this instrument. In this application, we present projects and preliminary data from studies that require access to high-throughput, high-content imaging. These projects include development of miniaturized assays that utilize 3D organotypic cultures for high-throughput screening, assessment of cellular signaling networks that regulate wound healing and tissue regeneration, identification of cellular factors that regulate the architecture of chromatin domains and gene expression during latent Herpes Virus infection, and nucleocytoplasmic shuttling of cellular cofactors involved in epithelial-to mesenchymal transition, migration and tumor metastasis. The purchase of the Operetta will greatly expand the capabilities and versatility of the Wistar Molecular Screening Facility and Microscopy facilities to support transformative research aimed to reduce the burden of human disease.

描述（由申请人提供）：资金要求购买珀金埃尔默轻歌剧台式自动化高通量，高内容成像系统。目前，没有这样的仪器可用于Wistar研究所或邻近的研究社区在宾夕法尼亚大学或德雷克塞尔大学。Wistar研究所最近建立了一个分子筛选设施，以支持在微量滴定板中筛选shRNA、siRNA、miRNA和小分子化学文库。该设施在开发利用全井读数的测定方面取得了很大进展。然而，无论是分子筛选还是Wistar研究所的显微镜设施都没有能力支持高含量筛选。此外，对邻近的宾夕法尼亚大学和德雷克塞尔医学院的一项调查表明，在我们的研究界，获得这项技术作为支持筛选实验的共享资源是不够的。Wistar的许多研究人员要求该设施将其能力扩展到高含量的基于细胞的筛选测定。请求的Operetta将位于Wistar研究所分子筛选设施，该设施成立于2008年，致力于维护支持系统生物学方法所需的自动化，高通量技术，以识别和验证细胞靶点和/或先导分子，以治疗人类疾病，包括癌症，糖尿病，炎症和动脉粥样硬化。Operetta的独特功能将大大扩展Wistar的成像能力，包括自动化高通量采集和图像数据的定量分析。最重要的是，Operetta将立即影响8个NIH资助的主要用户和一组未成年人用户开发基于细胞的高通量筛选检测的能力，这些检测专注于细胞及其分子组分的分析。一个由用户和Wistar研究所高级工作人员组成的内部咨询委员会将监督该工具的操作、维护和公平使用。在这个应用程序中，我们目前的项目和初步数据的研究，需要访问高通量，高内容的成像。这些项目包括开发利用3D器官型培养物进行高通量筛选的小型化测定，评估调节伤口愈合和组织再生的细胞信号传导网络，鉴定在潜伏性疱疹病毒感染期间调节染色质结构域和基因表达的细胞因子，以及参与上皮向间充质转化的细胞辅因子的核质穿梭，迁移和肿瘤转移。购买Operetta将大大扩展Wistar分子筛选设施和显微镜设施的能力和多功能性，以支持旨在减轻人类疾病负担的变革性研究。